EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer

被引：20

作者：

Boye, K. ^{[1
,2
]}

Nesland, J. M. ^{[3
,4
]}

Sandstad, B. ^{[5
]}

Haugen, M. Haugland ^{[1
]}

Mlandsmo, G. M. ^{[1
,6
]}

Flatmark, K. ^{[1
,7
]}

机构：

[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumour Biol, NO-0424 Oslo, Norway

[2] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, NO-0424 Oslo, Norway

[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, NO-0424 Oslo, Norway

[4] Univ Oslo, Fac Med, NO-0316 Oslo, Norway

[5] Oslo Univ Hosp, Norwegian Radium Hosp, Unit Biostat & Epidemiol, NO-0424 Oslo, Norway

[6] Univ Tromso, Fac Hlth Sci, Dept Pharm, NO-9037 Tromso, Norway

[7] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Surg Oncol, NO-0424 Oslo, Norway

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 04期

关键词：

EMMPRIN; S100A4; colorectal cancer; prognostic biomarker; MATRIX METALLOPROTEINASE INDUCER; SIGNAL-TRANSDUCTION MECHANISMS; DISSEMINATED TUMOR-CELLS; NF-KAPPA-B; TISSUE INHIBITORS; ADJUVANT THERAPY; POOR-PROGNOSIS; GROWTH-FACTOR; BONE-MARROW; METASTASIS;

D O I：

10.1038/bjc.2012.293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

BACKGROUND: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers. METHODS: The expression of extracellular matrix metalloproteinase inducer (EMMPRIN) was characterised using immunohistochemistry in primary tumours from a cohort of 277 prospectively recruited colorectal cancer patients, and associations with expression of S100A4, clinicopathological parameters and patient outcome were investigated. RESULTS: One hundred and ninety-eight samples (72%) displayed positive membrane staining of the tumour cells, whereas 10 cases (4%) were borderline positive. EMMPRIN expression was associated with shorter metastasis-free, disease-specific and overall survival in both univariate and multivariate analyses. The prognostic impact was largely confined to TNM stage III, and EMMPRIN-negative stage III patients had an excellent prognosis. Furthermore, EMMPRIN was significantly associated with expression of S100A4, and the combined expression of these biomarkers conferred an even poorer prognosis. However, there was no evidence of direct regulation between the two proteins in the colorectal cancer cell lines HCT116 and SW620 in siRNA knockdown experiments. CONCLUSION: EMMPRIN is a promising prognostic biomarker in colorectal cancer, and our findings suggest that it could be used in the selection of stage III patients for adjuvant therapy. British Journal of Cancer (2012) 107, 667-674. doi:10.1038/bjc.2012.293 www.bjcancer.com Published online 10 July 2012 (C) 2012 Cancer Research UK

引用

页码：667 / 674

页数：8

共 41 条

[1]

Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications [J].